- Immunotherapy in Head and Neck Squamous Cell Cancer
-
Denaro N, Merlano MC
- KMID: 2439847
- Clin Exp Otorhinolaryngol.
- 2018 Dec;11(4):217-223.
- doi: 10.21053/ceo.2018.00150
Prognosis in relapsed metastatic head and neck squamous cell cancer (RM-HNSCC) is dismal. Platinum based chemotherapy in combination with Cetuximab is used in first-line setting, while no further validated options... -
- CITED
-
- Close
- SHARE
-
- Close
- Follow-up in Head and Neck Cancer: Do More Does It Mean Do Better? A Systematic Review and Our Proposal Based on Our Experience
-
Denaro N, Merlano MC, Russi EG
- KMID: 2360758
- Clin Exp Otorhinolaryngol.
- 2016 Dec;9(4):287-297.
- doi: 10.21053/ceo.2015.00976
As the patients population ages, cancer screening increases, and cancer treatments improve, millions more head and neck carcinoma (HNC) patients will be classified as cancer survivors in the future. Change... -
- CITED
-
- Close
- SHARE
-
- Close
- Dysphagia in Head and Neck Cancer Patients: Pretreatment Evaluation, Predictive Factors, and Assessment during Radio-Chemotherapy, Recommendations
-
Denaro N, Merlano MC, Russi EG
- KMID: 2468431
- Clin Exp Otorhinolaryngol.
- 2013 Sep;6(3):117-126.
Progress in head and neck cancer (HNC) therapies has improved tumor response, loco-regional control, and survival. However, treatment intensification also increases early and late toxicities. Dysphagia is an underestimated symptom... -
- CITED
-
- Close
- SHARE
-
- Close
